MAP3K8 (Ab-400) Antibody

Shipped with Ice Packs
In Stock

Product Specs

Form
Rabbit IgG in phosphate buffered saline (without Mg2+ and Ca2+), pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol.
Lead Time
We typically dispatch orders within 1-3 business days of receipt. Delivery times may vary depending on the purchase method and location. Please consult your local distributor for specific delivery timeframes.
Synonyms
AURA2 antibody; c COT antibody; Cancer Osaka thyroid oncogene antibody; CCOT antibody; COT antibody; COT proto oncogene serine/threonine protein kinase antibody; EST antibody; ESTF antibody; Ewing sarcoma transformant antibody; FLJ10486 antibody; M3K8_HUMAN antibody; MAP3K 8 antibody; MAP3K8 antibody; MEKK8 antibody; Mitogen activated protein kinase kinase kinase 8 antibody; Mitogen-activated protein kinase kinase kinase 8 antibody; Proto oncogene cCot antibody; Proto-oncogene c-Cot antibody; Serine/threonine protein kinase cot antibody; Serine/threonine-protein kinase cot antibody; TPL 2 antibody; TPL-2 antibody; TPL2 antibody; Tumor progression locus 2 antibody
Target Names
Uniprot No.

Target Background

Function
MAP3K8 plays a crucial role in lipopolysaccharide (LPS)-induced, TLR4-mediated activation of the MAPK/ERK pathway in macrophages, leading to the production of the proinflammatory cytokine TNF-alpha (TNF) during immune responses. It is involved in regulating T-helper cell differentiation and IFNG expression in T-cells. Additionally, MAP3K8 contributes to host resistance to bacterial infection by negatively regulating type I interferon (IFN) production. In vitro studies have demonstrated that MAP3K8 activates the MAPK/ERK pathway in response to IL1 in an IRAK1-independent manner, resulting in up-regulation of IL8 and CCL4. MAP3K8 transduces CD40 and TNFRSF1A signals that activate ERK in B-cells and macrophages, potentially influencing immunoglobulin production. Furthermore, MAP3K8 may participate in the transduction of TNF signals that activate JNK and NF-kappa-B in certain cell types. In adipocytes, MAP3K8 activates the MAPK/ERK pathway in an IKBKB-dependent manner in response to IL1B and TNF, but not insulin, leading to the induction of lipolysis. MAP3K8 also plays a role in the cell cycle. Isoform 1 exhibits some transforming activity, albeit weaker than the activated oncogenic variant.
Gene References Into Functions
  1. Studies have shown that miR-130b suppresses vascular inflammation by targeting Tpl2. PMID: 28759810
  2. Research indicates that the binding of miR-589-5p to the MAP3K8 3'-UTR inhibits MAP3K8 expression and suppresses CD90+ cancer stem cells characteristics in hepatocellular carcinoma. PMID: 27835990
  3. RelAp43 interacts with the p105-ABIN2-TPL2 complex, and this complex is significantly disrupted in the presence of M protein. PMID: 29084252
  4. Transfection tests using miRNA-509-3p mimics or inhibitors in KGN cells have confirmed that miRNA-509-3p improves oestradiol (E2) secretion by inhibiting MAP3K8 expression. PMID: 27002000
  5. MAP3K8 signaling plays a role in maintaining lung homeostasis. PMID: 26300007
  6. The rs1042058 GG Crohn's disease -risk polymorphism in TPL2 results in a gain-of-function by increasing TPL2 expression and signaling, thereby amplifying Pattern recognition receptor -initiated outcomes. PMID: 26215868
  7. MAP3K8 is a direct target of miR-144-3p, and downregulation of miR-144-3p contributes to renal cell carcinoma progression through potentiation of MAP3K8 expression. PMID: 27717821
  8. Studies suggest that Cot kinase plays a critical role in Helicobacter pylori type IV secretion apparatus-dependent early IL-8 secretion and CagA-dependent late IL-8 secretion as an alternative signaling molecule in the Erk pathway. PMID: 28361341
  9. Evidence indicates that Tpl2, a MAP3K, participates in a wide range of cancer-related signaling pathways and promotes tumorigenesis and progression of many cancers. PMID: 25723737
  10. Research has demonstrated that the miR-509-3p RCC suppressor is a significant regulator of the MAP3K8 oncogene, suggesting its potential therapeutic role in the treatment of renal cell carcinoma. PMID: 25815776
  11. Findings provide a novel perspective on the role of the IL-33/ST2/COT signaling pathway in supporting cancer-associated inflammation in the tumor microenvironment. PMID: 25531326
  12. The structurally versatile active site of COT kinase significantly impacts the design of potent, low molecular weight COT kinase inhibitors. PMID: 25918157
  13. TPL2 mediates the phosphorylation of a fraction of nucleophosmin at threonine 199, an event required for its proteasomal degradation and maintenance of steady-state nucleophosmin levels. PMID: 24998852
  14. MAP3K8 and miR-17-5p expression levels were inversely correlated with treatment response. PMID: 24819603
  15. COT interacts with and phosphorylates Pin1 on Ser16. Consequently, Pin1 Ser16 phosphorylation by COT increases cyclin D1 abundance and enhances the tumorigenecity of MCF7 cells. PMID: 24265246
  16. Aberrant expression of A-, B-, and C-RAF, and COT is frequent in PTC; increased expression of COT is correlated with recurrence of PTC. PMID: 25674762
  17. Tpl2 overexpression and downregulation exhibited significant stimulatory and inhibitory effects on the tumorigenic and metastatic potential of ADI PC cells. PMID: 25274482
  18. Following epithelial injury, intestinal myofibroblasts sense innate or inflammatory signals and activate, via Tpl2, the cyclooxygenase-2 (Cox-2)-prostaglandin E2 (PGE2) pathway, which are essential for the epithelial homeostatic response. PMID: 25316791
  19. High MAP3K8 expression affects obesity-induced adipose tissue inflammation without systemic effects. PMID: 24586913
  20. Tpl2 regulates various inflammatory pathways by activating the ERK mediated MAP kinase pathway in innate immune cells such as macrophages and dendritic cells in humans but not in mice. PMID: 24642963
  21. Coregulation of TLR2 and TLR6 expression correlates with local processing of versican, a proteoglycan TLR2/6 agonist linked to carcinoma progression. PMID: 24723682
  22. Data indicate that Tpl2 kinase is associated with and contributes to disease progression of clear cell renal cell carcinoma. PMID: 23982215
  23. This report has defined a novel network leading to ERK1/ERK2 activation in cystic fibrosis airway epithelial cells in response to P. aeruginosa that involves both the TPL2 and EGFR protein kinases and contributes to inflammation of CF airways. PMID: 24404585
  24. MAP3K8 mediates the phosphorylation and repression of IRF3 homodimers to promote greater transcriptional activity through utilization of IRF3:IRF7 heterodimers. PMID: 24275658
  25. High Tpl2 expression is associated with peritoneal dissemination in gastric tumor. PMID: 23828905
  26. The protein kinase TPL2 is essential for ERK1/ERK2 activation and cytokine gene expression in airway epithelial cells exposed to pathogen-associated molecular patterns. PMID: 23527104
  27. Authors report constitutive activation of MAP3K8 kinase-dependent pathways that regulate the magnitude and extent of inflammatory activity of monocytes/macrophages within myeloma niches. PMID: 23252623
  28. TPL2 was found to antagonize oncogene-induced cell transformation and survival through a pathway involving p53 downstream of cJun N-terminal kinase (JNK) and be required for optimal p53 response to genotoxic stress. PMID: 23533274
  29. Overexpression of MAP3K8 is associated with early-onset colorectal cancer. PMID: 23322277
  30. High TPL2 expression is associated with tumor progression. PMID: 23125217
  31. MAP3K8 plays a role in GPCR-mediated Ca(2+) signaling and cell migration. PMID: 21868363
  32. Cot protein is responsible for the constitutive Erk1/2 activation in anaplastic large-cell lymphoma cells. PMID: 21741362
  33. OPN knockdown chemosensitized MDA-MB-231 cells to CTX, which is dependent on p38 MAPK pathway activation. PMID: 21539449
  34. TPL2 kinase plays a critical role in promoting androgen depletion-independent prostate cancer progression. PMID: 21267413
  35. Oncoprotein Cot1 represses kinase suppressors of Ras1/2 and 1,25-dihydroxyvitamin D3-induced differentiation of human acute myeloid leukemia cells. PMID: 20945381
  36. MAP3K8 (the gene encoding COT/Tpl2) has been identified as a MAPK pathway agonist that drives resistance to RAF inhibition in B-RAF(V600E) cell lines. PMID: 21107320
  37. Tensile strain and magnetic particle force application do not induce MAP3K8 and IL-1B differential gene expression in the same manner as fluid shear stress in human mesenchymal stem cells. PMID: 20603871
  38. MAP3 kinase COT1 is up-regulated by 1,25-dihydroxyvitamin D3 in parallel with activated c-jun during differentiation of human myeloid leukemia cells. PMID: 20227498
  39. Endogenous Tpl2 promotes efficient murine gammaherpesvirus 68 lytic replication through AP-1-dependent upregulation of RTA expression. PMID: 19939924
  40. Cot protein, expressed in HEK293 cells and immunoprecipitated, was used in a peptide-based substrate screening assay. The results of this assay suggested that Polo-like kinase 1 (Plk1) was a substrate of Cot. PMID: 19804365
  41. MAP3K8 contributes to LMP1-induced NF-kB signaling downstream of TRAF2. PMID: 11932422
  42. Research suggests that the activation of different signaling pathways by Cot and other MAP3Ks may be regulated separately, providing evidence for how such discrimination by one member of this kinase family occurs. PMID: 12138205
  43. Tpl2 is inhibited by and is a partner of NFkappab p105. PMID: 12667451
  44. hKSR-2, a new member of the KSR family, negatively regulates Cot-mediated MAP kinase and NF-kappaB pathway signaling. PMID: 12975377
  45. The COOH-terminal domain of wild-type Cot regulates its stability and kinase-specific activity. PMID: 14517305
  46. Optimal TPL-2 stability in vivo requires interaction with ABIN-2 as well as p105. PMID: 15169888
  47. Data support a role for MAP3K8 activity in cellular transformation, but suggest that mutational activation of the gene is a rare event in lung cancer. PMID: 15287022
  48. Phosphorylation of Cot at Thr-290 is necessary but not sufficient for full kinase activity in the MEK/ERK pathway. PMID: 15466476
  49. Tpl2/Cot is overexpressed in large granular lymphocyte proliferative disorders but not other T-cell neoplasias. PMID: 15575964
  50. These results indicate a distinction between TNF Receptor family members CD40 and TNFR1 in their utilization of MAP3Ks, and demonstrate TRAF-dependence of Tpl2 association with the CD40 receptor complex. PMID: 15670770
Database Links

HGNC: 6860

OMIM: 191195

KEGG: hsa:1326

STRING: 9606.ENSP00000263056

UniGene: Hs.432453

Protein Families
Protein kinase superfamily, STE Ser/Thr protein kinase family, MAP kinase kinase kinase subfamily
Subcellular Location
Cytoplasm.
Tissue Specificity
Expressed in several normal tissues and human tumor-derived cell lines.

Q&A

What is the specificity of the MAP3K8 (Ab-400) antibody, and how is it validated?

The MAP3K8 (Ab-400) antibody is a rabbit polyclonal antibody designed to detect endogenous levels of MAP3K8 protein, specifically targeting the phosphorylation site at serine 400 (Ser400). Its specificity has been validated through affinity purification using epitope-specific immunogens. Validation studies have demonstrated its efficacy in applications such as Western blotting (WB) and immunohistochemistry (IHC), ensuring reliable detection of MAP3K8 protein across various experimental conditions .

Validation data typically include experiments such as Western blot analysis on cell extracts treated with specific stimuli like insulin or environmental stressors. For example, IHC analysis on human ovarian cancer samples confirmed the antibody's ability to selectively bind MAP3K8 protein in clinical specimens . Such validations underpin its reliability for academic research.

How can researchers optimize experimental conditions when using MAP3K8 (Ab-400) antibody?

Optimizing experimental conditions involves tailoring antibody dilutions, incubation times, and buffer compositions to specific applications. For Western blotting, recommended dilutions range from 1:500 to 1:3000 depending on the target protein concentration and detection sensitivity required . For IHC applications, dilutions between 1:50 and 1:100 are suggested .

Buffer composition plays a critical role in maintaining antibody stability and enhancing binding efficiency. The antibody formulation includes phosphate-buffered saline (PBS) devoid of magnesium and calcium ions, supplemented with sodium azide as a preservative and glycerol for cryoprotection . Researchers should store aliquots at -20°C to prevent freeze-thaw cycles that could degrade antibody activity.

Experimental optimization also requires pilot studies to determine the ideal incubation times and temperatures. For instance, prolonged incubation at lower temperatures can enhance binding specificity during IHC assays. Additionally, blocking steps using bovine serum albumin (BSA) or non-fat milk can minimize non-specific binding.

What are the primary applications of MAP3K8 (Ab-400) antibody in academic research?

The MAP3K8 (Ab-400) antibody is primarily used for Western blotting (WB), immunohistochemistry (IHC), and enzyme-linked immunosorbent assay (ELISA). These applications allow researchers to investigate protein expression patterns, post-translational modifications, and signaling pathway dynamics in various biological contexts.

Western Blotting

Western blotting with MAP3K8 (Ab-400) enables quantitative analysis of protein expression under different experimental conditions. For example, studies have used this antibody to examine MAP3K8 activation in response to inflammatory stimuli like lipopolysaccharides (LPS) or cytokines such as IL-1 .

Immunohistochemistry

IHC applications facilitate spatial localization of MAP3K8 protein within tissue samples. In cancer research, IHC has been employed to correlate MAP3K8 expression with tumor progression and immune infiltration patterns .

ELISA

ELISA assays using this antibody provide high-throughput quantification of phosphorylated MAP3K8 levels across multiple samples. This application is particularly useful for screening drug candidates targeting the MAPK/ERK pathway .

How does phosphorylation at Ser400 influence the functional activity of MAP3K8?

Phosphorylation at Ser400 is a critical regulatory event that modulates the kinase activity of MAP3K8 within signaling pathways such as the mitogen-activated protein kinase (MAPK) cascade. This post-translational modification enhances the ability of MAP3K8 to activate downstream targets like ERK and JNK kinases .

Functional studies have shown that Ser400 phosphorylation is essential for mediating immune responses through TLR4 signaling in macrophages, leading to TNF-alpha production . Additionally, phosphorylation at this site influences T-helper cell differentiation by regulating IFNG expression . These findings underscore the importance of Ser400 as a functional hotspot within MAP3K8's structure.

What experimental controls are necessary when studying MAP3K8 signaling pathways?

Experimental controls are indispensable for ensuring data reliability when investigating MAP3K8 signaling pathways. Key controls include:

Negative Controls

Using cell lines or tissue samples devoid of MAP3K8 expression serves as a baseline to assess non-specific binding by the antibody.

Positive Controls

Samples treated with known activators of MAP3K8, such as IL-1 or TNF-alpha, provide benchmarks for validating pathway activation.

Isotype Controls

Rabbit IgG isotype controls help distinguish specific binding from background noise during IHC or ELISA assays .

Loading Controls

For Western blotting experiments, loading controls like beta-actin or GAPDH ensure equal protein loading across lanes.

By incorporating these controls into experimental designs, researchers can mitigate artifacts and improve data reproducibility.

How does differential expression of MAP3K8 correlate with disease progression?

Differential expression of MAP3K8 has been implicated in various diseases, including cancers and inflammatory disorders. Elevated levels of MAP3K8 are associated with tumorigenesis through its role in promoting cell proliferation and survival via the ERK pathway .

In renal clear cell carcinoma (ccRCC), high expression levels of MAP3K8 correlate with poor prognosis due to its protumorigenic effects on immune evasion mechanisms . Conversely, reduced expression levels may impair immune responses by limiting cytokine production during bacterial infections . These dual roles highlight the complexity of MAP3K8's involvement in disease pathology.

What bioinformatics tools can be used to analyze MAP3K8-related datasets?

Bioinformatics tools offer powerful platforms for analyzing gene expression profiles, mutation landscapes, and interactive networks related to MAP3K8:

Gene Expression Analysis

Platforms like TIMER2.0 and UALCAN enable differential expression analysis across diverse tissue types and disease states .

Mutation Profiling

Tools such as DriverDBv3 and cBioPortal provide insights into mutation frequencies and their functional impacts on signaling pathways involving MAP3K8 .

Protein Interaction Networks

GeneMANIA and Cytoscape facilitate visualization of protein-protein interaction networks associated with MAP3K8, revealing potential regulatory mechanisms .

By leveraging these tools, researchers can uncover novel insights into the biological roles of MAP3K8.

How can researchers address contradictory data regarding MAP3K8's role in immune responses?

Contradictory findings often arise due to variations in experimental models, assay conditions, or genetic backgrounds. Addressing these discrepancies requires:

Comparative Studies

Conducting side-by-side comparisons using standardized protocols can help reconcile differences between datasets.

Replication Studies

Independent replication using diverse sample cohorts ensures robustness of observed phenomena.

Mechanistic Investigations

Focusing on upstream regulators or downstream effectors may clarify conflicting roles attributed to MAP3K8 in immune responses.

For example, while some studies suggest that high levels of MAP3K8 promote tumor immunity by activating NK cells, others report protumorigenic effects through regulatory T cells . Detailed mechanistic studies are essential for resolving such contradictions.

Table 1: Recommended Experimental Conditions for Using Anti-MAP3K8 Antibody

ApplicationDilution RangeBuffer CompositionStorage Conditions
WB1:500–1:3000PBS + Sodium Azide-20°C
IHC1:50–1:100PBS + Glycerol-20°C
ELISA1:10000PBS-20°C

Quick Inquiry

Personal Email Detected
Please use an institutional or corporate email address for inquiries. Personal email accounts ( such as Gmail, Yahoo, and Outlook) are not accepted. *
© Copyright 2025 TheBiotek. All Rights Reserved.